Citi‘s Most Read - Healthcare

Research evidence excerpt

Citi‘s Most Read - Healthcare

Roundup |

Citi's Most Read - Healthcare

July 6 - July 12 13 Jul 2026 05:48:50 ET

ACMost Read Citi Global Research

As boundaries increasingly blur between conventional sectors, and as bottom-up +44-20-7500-1400

and top-down analysis converges, Citi Research offers a Super-Sector lens to help

you better understand and take advantage of widespread disruptive trends and

innovation, extending our peer analysis for greater breadth and depth. The

Healthcare Super-Sector consists of the Pharmaceuticals & Biotechnology,

Medical Services, Medical Supplies, Medical Technology, and Life Sciences

sectors. Please find below a collection of our most impactful recent research in the

Healthcare Global Super-Sector – we hope you find it thought-provoking.

Most Read

North America Life Science Tools & Diagnostics - 2Q26 Preview: Optimism Once

Again for Gradual (Glacial?) Recovery to Arrive

From our conversations, investor appetite appears to be slowly returning across

our coverage after an underwhelming 1Q and concerns of AI disruption, with

cautious optimism for the elusive end-market recovery to materialize. To help

understand 2H dynamics, we conducted a proprietary survey with Citi’s Research

Innovation Lab regarding ordering patterns and expectations, with a focus on

instrumentation ahead of reshoring timelines and bioprocessing trends.

Sentiment on AI for Tools is gradually turning positive, with the view that AI could

accelerate drug development and support re-investments into R&D pipelines. CRO

interest remains on the lighter side with AI overhangs persisting despite sustained

higher biotech funding. Heading into 2H, we reiterate WAT/WST as our top Life

Science picks, GH our top Diagnostic pick, and CRL our top CRO pick (adding